A Study to Determine if an Investigational Pain Medicine Provides Relief of Chronic Pain After a Shingles Outbreak

A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Flexible Escalating -Dose, Pilot Analgesic Efficacy Study of T-62 in Subjects With Postherpetic Neuralgia

The purpose of this study is to determine whether T-62 is effective in providing relief of pain that can occur after an individual experiences a shingles outbreak, which is an infection in adults caused by the same virus that causes chicken pox.

Inclusion Criteria:

• Has a clinical diagnosis of Postherpetic Neuralgia (PHN)
• Experiencing pain for at least 3 months after the healing of shingles rash
• Has at least a weekly average pain intensity of equal to or greater than 4 out of 10
• Females must not be pregnant or breastfeeding and practicing an acceptable method of birth control, or be surgically sterile or post-menopausal
• Will not consume grapefruit or grapefruit juice during the study

Exclusion Criteria:

• Has a current acute or unstable chronic disease other than Postherpetic Neuralgia (PHN)
• Has clinically important medical disorder
• Uses certain types of medications for heart conditions
• Unwilling/unable to discontinue use of medications for treatment of neuropathic pain
• Has a history of hypersensitivity to any medication or soy product
• Has liver or kidney disease
• Has asthma that required treatment within the last year
• Has HIV or hepatitis (other than hepatitis A)
• Has a history of alcohol abuse within the past 2 years
• Has a history of (within last 2 years) or currently abuses prescription or illegal drugs